Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYMAKER-U04 sub-study 04D: MK-3120 + enfortumab vedotin + pembrolizumab in first-line advanced/metastatic urothelial carcinoma
MOH_2025-12-02_015510Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Nov 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of MK-3120, enfortumab vedotin and pembrolizumab in transitional cell carcinoma (TCC) (3 arms), sponsored by Merck & Co. Primary endpoints: Objective response rate, Safety and 1 more. Started Nov 2025; status: recruiting.
02
Drugs
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on MOH_2025-12-02_015510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-12-02_015510.